AZTR

Common Stock Will Begin Trading on a Split-Adjusted Basis on October 26, 2026BRANFORD, Conn., Oct. 16, 2026 /PRNewswire/ -- Azitra, Inc. (NYSE:AZTR), a clinical-stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today announced that it intends to effect a reverse stock split of its common stock at a ratio of 1 post-split share for every 10 pre-split shares. The reverse stock split will become effective at 12:01 A.M. Eastern Time, on October 26, 2026. The Company's common stock will continue to be traded on the NYSE American under the symbol "AZTR" and will begin trading on a split-adjusted basis when the market opens on October 26, 2026. The

8-K - Azitra, Inc. (0001701478) (Filer)

BRANFORD, Conn., Oct. 1, 2026 /PRNewswire/ -- Azitra, Inc. ("Azitra" or the "Company") (NYSE:AZTR), a clinical-stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today announced the completion of Cohort 1 in its Phase 1/2 clinical trial evaluating ATR04-484 as a potential treatment for EGFR inhibitor (EGFRi)-associated skin rash. Following its review of available safety data from patients enrolled in Cohort 1, the study's safety review committee recommended that the trial may proceed to Cohort 2, enabling Azitra to begin enrollment and dosing in the second cohort.The multicenter, randomized, double-blind, vehicle-controlled Phase 1/2 clinica

8-K - Azitra, Inc. (0001701478) (Filer)

424B5 - Azitra, Inc. (0001701478) (Filer)

8-K - Azitra, Inc. (0001701478) (Filer)

BRANFORD, Conn., Sept. 8, 2026 /PRNewswire/ -- Azitra, Inc. ("Azitra" or the "Company") (NYSE:AZTR), a clinical-stage biopharmaceutical company focused on developing innovative therapies for precision dermatology and high value cosmetic proteins and peptides, today announced that Travis Whitfill Ph.D., MPH, Azitra's Co-founder and Chief Operating Officer, will deliver a virtual presentation at the H.C. Wainwright 28th Annual Global Investment Conference, to be held from September 14-16, 2026, in New York City. In the prerecorded presentation, Dr. Whitfill will provide an update on Azitra's recent progress and key pipeline activ

8-K - Azitra, Inc. (0001701478) (Filer)

BRANFORD, Conn., Aug. 21, 2026 /PRNewswire/ -- Azitra, Inc. ("Azitra" or the "Company") (NYSE:AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology and high value cosmetic proteins and peptides, today announced that it has received written notification from NYSE American LLC ("NYSE American") confirming that the Company has regained compliance with all of the NYSE American continued listing standards set forth in Part 10 of the NYSE American Company Guide. In a letter dated August 19, 2026, NYSE Regulation informed Azitra that the Company has resolved the previous

SCHEDULE 13G - Azitra, Inc. (0001701478) (Subject)

SCHEDULE 13G - Azitra, Inc. (0001701478) (Subject)

BRANFORD, Conn., Aug. 12, 2026 /PRNewswire/ -- Azitra, Inc. ("Azitra" or the "Company") (NYSE:AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology and high value cosmetic proteins and peptides, today reported financial results for the quarter ended June 30, 2026, and provided a business update. Q2 2026 and Recent Business HighlightsReported the first preclinical data from ATR-COSF demonstrating breakthrough repeat-dose distribution, controlled delivery into targeted skin layers and anti-wrinkle activity in ex vivo human skin, supporting advancement toward a plann

8-K - Azitra, Inc. (0001701478) (Filer)

10-Q - Azitra, Inc. (0001701478) (Filer)

8-K - Azitra, Inc. (0001701478) (Filer)

In the news release, Azitra, Inc. Announces Breakthrough Repeat Dose and Anti-Wrinkle Ex Vivo Results for ATR-COSF Program, Demonstrating Increased Distribution and Elasticity, issued 15-Jul-2026 by Azitra, Inc. over PR Newswire, we are advised by the company that changes have been made. The complete, corrected release follows, with additional details at the end: Azitra, Inc. Announces Breakthrough Repeat Dose and Anti-Wrinkle Ex Vivo Results for ATR-COSF Program, Demonstrating Increased Distribution and Elasticity ATR-COSF uses a supernatant based formulation containing an active recombinant human domain of the protein, filaggrin ("rHDfilaggrin"). This S. epidermis derived supernatant is in

ATR-COSF uses a supernatant based formulation containing an active recombinant human domain of the protein, filaggrin ("rHDfilaggrin"). This S. epidermis derived supernatant is in development as a high value cosmetic ingredientEx vivo data successfully showed controlled distribution of the rHDfilaggrin into the stratum granulosum in increased amounts over prior single dose experiments in human skin Single dose ex vivo experiments established improvements in elasticity and reduced the appearance of new fine lines and wrinkles in human skin BRANFORD, Conn., July 15, 2026 /PRNewswire/ -- Azitra, Inc. (NYSE:AZTR), a clinical stage biopharmaceutical company focused on developing innovative therap

SCHEDULE 13G - Azitra, Inc. (0001701478) (Subject)

4 - Azitra, Inc. (0001701478) (Issuer)

8-K - Azitra, Inc. (0001701478) (Filer)

BRANFORD, Conn., June 17, 2026 /PRNewswire/ -- Azitra, Inc. ("Azitra" or the "Company") (NYSE:AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today announced that Francisco Salva, Chief Executive Officer of Azitra, has issued a Letter to Shareholders detailing the Company's strategic growth initiatives, recent accomplishments and outlook for 2026 and beyond. The full text of the letter follows. A MESSAGE FROM OUR CHIEF EXECUTIVE OFFICERTo my fellow shareholders,The first half of 2026 signaled an important inflection point in Azitra's history. During this pe

BRANFORD, Conn., June 16, 2026 /PRNewswire/ -- Azitra, Inc. (NYSE:AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today announced that Cofounder and Chief Operating Officer, Travis Whitfill Ph.D., MPH, will present at BIO International Convention, being held June 22-25, 2026, in San Diego, California. The presentation will highlight recent updates and progress in Azitra's pipeline, including the launch of an innovative protein and peptide program for the cosmetic and cosmeceutical markets leveraging proprietary filaggrin technologies.Presentation Details:Ev

8-K - Azitra, Inc. (0001701478) (Filer)

DEFA14A - Azitra, Inc. (0001701478) (Filer)

8-K - Azitra, Inc. (0001701478) (Filer)